The burden of AD is different for everyone

Not all patients experience the same AD symptoms, which is one of the reasons it can be difficult to treat. Here are some statistics that may surprise you:

In a cross-sectional study assessing burden of disease in (n=1434) patients with moderate to severe AD:

Only 12%

of adult patients with AD are meeting all treatment targets1*


of adult patients with WP-NRS ≤4 while on treatment still reported AD had a moderate to very large impact on their quality of life1†

Based on a longitudinal observational study (n=801) that combined patient surveys and healthcare claims data:


of adult patients on treatment experienced at least 1 or more flares over the past month2

*Researchers assessed the proportions of patients that met 6-month disease domain treatment targets of EASI ≤7, SCORAD ≤24, WP-NRS ≤4, POEM ≤7, and DLQI ≤5.1

Researchers used Dermatology Life Quality Index (DLQI) to assess quality of life.1

Flares were defined as any of the following: diagnosis for contact dermatitis because of an unspecified condition, or rash and other nonspecific skin eruption.2

“On treatment, this may be the best they’ve ever felt, but that doesn’t mean they’re well controlled.”– Dr. Seminara

Clearer skin doesn't necessarily mean less itch

Even though some of your patients may show rash improvement, they can still experience itch—and that could be a sign of uncontrolled AD. These patients are itching for change and often use workarounds, like avoiding certain activities and triggers (examples include humidity, irritants, and allergens), to help improve their quality of life.3

According to a prospective practice-based 2021 study in 592 adults with AD, on average:


of patients with clear or almost clear skin reported having moderate to very severe itch4

In a PRO study assessing disease burden in 380 patients with moderate to severe AD:


experienced itch ≥12 hours
per day


reported itch was severe
or unbearable

§Researchers used Dermatology Life Quality Index (DLQI) to assess quality of life and found that AD significantly impaired patients’ quality of life.5

Hear about the burdens of AD faced by 3 individuals in the powerful documentary, "Under My Skin."

"I would always fall asleep in school because I would be up all night scratching."

AD=atopic dermatitis; DLQI=Dermatology Life Quality Index; EASI=Eczema Area and Severity Index; POEM=Patient-Oriented Eczema Measure; PRO=patient-reported outcome; SCORAD=SCORing Atopic Dermatitis; WP-NRS=Worst Pruritus Numerical Rating Scale.

Improvement in WP-NRS ≥4=improvement (reduction) in WP-NRS ≥4 points from baseline in patients with NRS >4 at baseline.


  1. de Bruin-Weller MS, Lauffer F, Criado RFJ, et al. Real-world achievement of atopic dermatitis treat-to-target disease domain criteria: results from a multicountry study. Presented at: 4th Annual Revolutionizing Atopic Dermatitis Conference (RAD 2022); April 9-11, 2022; Baltimore, MD.
  2. Wei W, Ghorayeb E, Andria M, et al. A real-world study evaluating adeQUacy of existing systemic treatments for patients with moderate-to-severe atopic dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment. Ann Allergy Asthma Immunol. 2019;123(4):381-388. doi:10.1016/j.anai.2019.07.008
  3. McCleary KK. The More Than Skin Deep "Voice of the Patient" Report. March 2020. Accessed January 17, 2024.​mtsd_report_-_digital_file_1.pdf
  4. Chovatiya R, Lei D, Ahmed A, Chavda R, Gabriel S, Silverberg JI. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. Ann Allergy Asthma Immunol. 2021;127(1):83-90.e2. doi:10.1016/j.anai.2021.03.019
  5. Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491-498. doi:10.1016/j.jaad.2015.10.043